Jinan Bekir, M.D. Amma Kyei-Mensah, M.D. Seang-Lin Tan, M.D.
|
|
- Brice Howard
- 6 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY Copyright ~ 1995 American Society for Reproductive Mediciue Vol. 64, No.4, October 1995 Printed on acid-free paper in U. S. A. Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin-releasing hormone agonist in in vitro fertilization-a prospective randomized study Adel G. Shaker, M.D. Rudiger Pittrof, M.D. Jamal Zaidi, M.D. Jinan Bekir, M.D. Amma Kyei-Mensah, M.D. Seang-Lin Tan, M.D. The London Women's Clinic, London, United Kingdom Objective: To assess the effect of administration of adjuvant 1M progestogen to patients undergoing IVF who were not pituitary desensitized after 14 days of GnRH agonist (GnRH-a) administration. Design: Prospective randomized study. Setting: A tertiary referral center for assisted conception. Patients: Forty-nine patients undergoing 51 IVF treatment cycles. Intervention: Patients in whom the endometrial thickness was >5 mm or who had an ovarian cyst> 15 mm after 14 days of GnRH-a administration were recruited if the serum E2 concentration was >27.24 pg/ml (>100 pmolll). Patients in group 1 (n = 22) received a single 1M injection of 100 mg P whereas patients in group 2 (n = 29) did not. Patients in both groups continued to receive SC GnRH-a 500 j.lg/d and had serum E2levels measured every 3 days until the concentrations were ::;;;100 pmolll. Main Outcome Measures: The number of days of GnRH-a administration from recruitment until serum E2 concentration measured::;;; 100 pmolll, number of cycles with withdrawal bleeding, number of days from recruitment to withdrawal bleeding, total dose of hmg used, number of follicles > 14 mm, number of oocytes, number of embryos, and pregnancy rates per cycle commenced and per ET. Results: There were no significant differences in all the above parameters except in the mean number of days from recruitment to onset of withdrawal bleeding, which were 5.33 ± 0.7 (mean ± SEM) and 8.62 ± 1.26 days in groups 1 and 2, respectively. The pregnancy rate per ET was higher in group 1 (38.88%) when compared with group 2 (19.04%). However, this difference was not statistically significant. Conclusions: Adjuvant administration of a single 1M injection of progestogen hastens the onset of withdrawal bleeding in patients who are not pituitary desensitized after 2 weeks of administration of SC GnRH-a. It does not appear to affect the length of time the serum E2 concentrations take to reach basal levels or to alter the ovarian responsiveness to exogenous gonadotropins. Fertil Steril 1995;64:791-5 Key Words: In vitro fertilization, progestogen, pituitary desensitization, gonadotropin releasing hormone agonist Most IVF programs use some form of ovarian stimulation to induce multiple follicular development. This is because, in general, the more oocytes that are recovered the more embryos will be available for transfer or cryopreservation, with an attendant Received December 13, 1994; revised and accepted May 4, * Reprint requests: Adel G Shaker, M.D., The London Women's Clinic, 113/115 Harley Street, London WIN 1DG, United Kingdom (FAX: ). increase in pregnancy rates (PRs). In the past, hmg with or without clomiphene citrate was the stimulation regimen most commonly used. This has been replaced increasingly in recent years by the use of combined GnRH agonist (GnRH-a) and hmg, which has been reported to be associated with higher pregnancy and live birth rates (1). Although GnRH-a and hmg can be used in various protocols, the one most commonly used is the long protocol, which has been reported by various groups to lead to an increase in Vol. 64, No.4, October 1995 Shaker et al. Progestogens and pituitary desensitization in NF 791
2 the number of oocytes collected, an improvement in PRs, and a reduction in miscarriage rates (1-4). The long protocol of GnRH-a administration allows greater flexibility in timing of hcg administration (5), thus reducing the amount of monitoring necessary and permitting weekend oocyte collections to be avoided largely (6, 7). This allows simplification of IVF therapy (8). The aim of the long protocol is to achieve pituitary desensitization using GnRH-a before commencing ovarian stimulation with hmg. This, in practice, generally is determined by measuring serum E2 concentrations, which should be at basal levels (: pg/ml [:5100 pmolll]). Although the majority of patients achieve pituitary desensitization within 10 to 14 days (9), a number of them (estimated to be ~20% ofivf treatment cycles in our program) are not desensitized after 2 weeks. As a result, the treatment cycle is prolonged, much to the inconvenience of the patient. In some cases, the delay in commencement of hmg may be >3 weeks, which adds to the patient's anxiety and stress. In these patients, the endometrium is often thick (>5 mm) and there may be an associated ovarian cyst present. With continued administration of the GnRH-a, these patients generally have a menstrual bleed that is associated with a decline of serum E2 levels and thinning of the endometrium. We postulated that the administration ofprogestogens to these patients may increase the likelihood of withdrawal bleeding or reduce the length of time required for withdrawal bleeding to occur and, in doing so, hasten the decline of serum E2 to basal levels. We, therefore, designed a prospective randomized study to test this hypothesis. MATERIALS AND METHODS Over a period of 8 months (March to October 1994), 49 patients who underwent 51 IVF treatment cycles were recruited into the study, which had been approved by the Institutional Ethical Committee. All patients had a baseline vaginal ultrasound (US) scan on either day 2 or 3 of the cycle to exclude relevant uterine or ovarian pathology. Subcutaneous administration of the GnRH-a, buserelin acetate (Suprefact; Hoechst, Hounslow, United Kingdom) was commenced the same day in a dose of 500 J1g daily. A second US scan was performed 14 days later. If, on the second US scan, an ovarian cyst> 15 mm in diameter was noted or an endometrial thickness >5 mm was seen, the serum E2 levels were checked the same day. If the serum E2 concentration was >27.24 pg/ ml (> 100 pmolll), the patient was recruited into the study and informed consent was taken. The patients were randomized prospectively to one of two groups. Randomization was done by drawing sequentially r labeled sealed envelops, each containing a number obtained from a table of random numbers. Patients : in group 1 continued receiving buserelin acetate in the same dose and were given an 1M injection of 100 mg P (Gestone; Paines & Byrne Limited, Surrey, United Kingdom). Patients in group 2 continued receiving SC buserelin acetate but did not have any progestogen. Other than the injection of P, all patients in the study were treated in exactly the same way. All patients were reviewed 6 days later by having a repeat US scan and measurement of the serum E2 concentration. The endometrial thickness and the mean diameter of any ovarian cyst were recorded at the time of US scan. If the serum E2 concentration remained >27.24 pg/ml (>100 pmol/l), it was measured every 3 days subsequently, until the level was : pg/ml (:5100 pmol/l). Once the serum E2 concentration was : pg/ml (:5100 pmol/l), hmg was commenced at the appropriate dosage, depending on the patient's age, her baseline serum FSH level, and her response to stimulation in previous treatment cycles. All patients were regularly monitored by US scans until three follicles with a mean diameter ~ 18 mm were seen when 10,000 IU hcg was administered. Serum E2 levels were measured on the day of hcg administration to assess the potential risk of ovarian hyperstimulation syndrome (OHSS). Patients who had serum E2 concentrations > pg/ml (18,000 pmol/l) or serum E2 levels > pg/ml (13,000 pmol/l) and ~20 oocytes collected were advised to have their oocytes collected but all their embryos frozen for transfer in a subsequent cycle. In cases of poor ovarian response (less than three follicles ~ 14 mm in diameter), the cycle was canceled or converted to lui provided the patient's fallopian tubes were patent. Oocyte collection and ET were performed as described previously (10, 11). The two groups were compared with regard to the serum E2 levels on the day of recruitment, number of days of buserelin acetate administration from recruitment to serum E2 : pg/ml (:5100 pmol! L) (days to desensitization), time from recruitment to onset of withdrawal bleeding, endometrial thickness, and mean diameter of ovarian cyst on the day of recruitment and 6 days later. Response to ovarian stimulation was assessed in terms of the number of days of hmg administration; the total number of hmg ampules administered; number of follicles, 00- cytes, and embryos; and the PRs. Results were analyzed using the nonparametric Mann-Whitney U test to compare the means and X 2 test to compare the PRs. A value of P < 0.05 was deemed significant. RESULTS There were 22 treatment cycles in group 1 and 29 treatment cycles in group 2. The age of the patients, 792 Shaker et al. Progestogens and pituitary desensitization in NF Fertility and Sterility
3 Table 1 Demographic Characteristics of Patients in Group 1 (Buserelin Acetate and Gestone) and Group 2 (Buserelin Acetate Only) No. of cycles Mean age (y) Length of infertility (y) No. of previous IVF cycles Cause of infertility (No. of patients) Tubal disease Unexplained Male factor Endometriosis Group :+: 0.86* 5.82 :+: :+: * Values are means:+: SEM. t Not significantly different in all categories. Group :+: 0.69t 5.52 :+: :+: 0.41 duration of infertility, number of previous treatment cycles, and indications for IVF were comparable in the two groups (Table 1). The mean:::'::: SEM serum E2 concentration on the day of recruitment was :::'::: pg/ml (2, :::'::: pmol/l) in patients in group 1 compared with :::'::: pg/ ml (1, :::'::: pmol/l) in patients in group 2. The difference was not statistically significant. There was no significant difference in the mean endometrial thickness on the day of recruitment in group 1 as compared with group 2 (8.9 :::'::: 0.6 versus 8.93 :::'::: 0.38 mm). Both serum E2 concentration and endometrial thickness were assessed in all patients 6 days after recruitment. Patients in group 1 had a reduction in mean serum E2 levels to :::'::: pg/ml ( :::'::: pmol/l) compared with :::'::: pg/ml ( :::'::: pmol/l) for those in group 2. The mean endometrial thickness in group 1 after 6 days was 5.5 :::'::: 0.63 mm (mean reduction of 3.09 :::'::: 0.41 mm) compared with 6.38 :::'::: 0.51 mm in group 2 (mean reduction of 2.39 :::'::: 0.33 mm). The mean diameter of any ovarian cyst seen (21 in group 1 and 23 in group 2) on the day of recruitment was :::'::: 2.07 and 23.9 :::'::: 1.78 mm in patients in groups 1 and 2, respectively. Six days later there was little change in the mean diameter of the cysts with the mean diameter being :::'::: 2.1 and :::'::: 1.26 mm in groups 1 and 2, respectively. There was no significant difference in the mean number of days between recruitment and serum E2 concentrations,,; pg/ml (,,;100 pmol/l) in group 1 (12.05 :::'::: 1.11 days) and group :::'::: 1.14 days) (Table 2). The percentage of patients with withdrawal bleeding was 95.23% of cycles in group 1 and 76% in group 2. The length of time from recruitment to onset of withdrawal bleeding was significantly less in group 1 (5.33 :::'::: 0.7 days) compared with group 2 (8.62 :::'::: 1.26 days) (Table 2). The patients' response to ovarian stimulation, in terms ofthe duration ofhmg Table 2 Comparison of Desensitization in Group 1 (Buserelin Acetate and Gestone) and Group 2 (Buserelin Acetate Only) Group 1 Group 2 Endometrial thickness (mm) Day :!:: 0.6t 8.93 :!:: 0.38:j: Day :!:: :!:: 0.51:1: Mean reduction (day 0 to day 6) 3.09 :!:: :!:: 0.33:j: Day ofhcg 9.98 :!:: :!:: 0.35:1: E2 levels (pg/ml) Day :!:: :!:: 56.39:j: Day :!:: :!:: l1.95:j: Day :!:: :!:: 12.1O:j: Day :!:: :!:: 7.01:j: Day :!:: :!:: 2.87:j: Day :!:: :!:: 2.49:j: Day :!:: :!:: 2.19:j: Day ofhcg 2, :!:: , :!:: Days from recruitment to Serum E2,;27.24 pg/ml :!:: :!:: 1.14:j: Serum E2,;40.86 pg/ml 10.5 :!:: :!:: 0.95:j: Serum E pg/ml 9.41 :!:: :!:: 0.86:1: Patients with withdrawal bleed (%) :j: Days from recruitment to onset of withdrawal bleeding 5.33 :!:: :!:: * Day 0 refers to the day of recruitment into the study, day 6 is 6 days later, and so on. t Values are means :!:: SEM. :I: Not significantly different. Conversion factor to SI unit, II Significantly different at P = treatment; total number of ampules of hmg used; number of follicles and oocytes; and number of embryos generated, transferred, or frozen were similar in both groups (Table 3). The endometrial thickness and serum E2 levels were comparable in the two groups on the day of hcg administration (Table 2). Ovarian cysts (> 10 mm in diameter) were still present in 34 patients (66.66%) at the start ofhmg therapy (18 patients in group 1 and 16 in group 2) % of those who had a cyst at the beginning of hmg stimulation became pregnant compared with Table 3 Outcome of Treatment in Group 1 (Buserelin Acetate and Gestone) and Group 2 (Buserelin Acetate Only) Group 1 Group 2* Days ofhmg :+: 0.51* :+: 0.37 NS Total number of hmg ampules :+: :+: 3.79 NS Follicles> 14 mm 8.14 :+: :+: 0.84 NS Oocytes retrieved 9.82 :+: :+: 1.09 NS Embryos generated 4.36 :+: :+: 0.55 NS Embryos transferred 2.18 :+: :+: 0.22 NS Embryos frozen 0.77 :+: :+: 0.39 NS No.ofETs NS Pregnancy rate per cycle 7/22 (31.81):j: 4/29 (13.79) NS Pregnancy rate per ET 7/18 (38.88) 4/21 (19.04) NS * Group 2 not significantly different from group 1. t Values are means:+: SEM. :j: Values in parentheses are percentages. Vol. 64, No.4, October 1995 Shaker et al. Progestogens and pituitary desensitization in IVF 793
4 5.88% of those who did not have a cyst. In group 1, two cycles were abandoned due to poor response, one due to failure of embryo cleavage, and all embryos were frozen in one cycle. In group 2, three cycles were converted to lui, one was abandoned for poor response, two for failed fertilization, and two ended in having all embryos frozen because of the increased risk of OHSS. Both patients who had all embryos frozen in group 2 became pregnant subsequently after receiving frozen-thawed embryos in frozen ET cycles. The PRs per cycle commenced and per ET were higher in group 1 (31.81% and 38.88%) compared with group 2 (13.79% and 19.04%). The differences between these rates were not statistically significant. DISCUSSION In vitro fertilization has helped thousands ofinfertile couples conceive. Most patients undergoing treatment are highly motivated and willing to endure the demands associated with treatment both in terms of the emotional as well as time commitment. Indeed many patients return for a second course of IVF treatment after having achieved a previous IVF baby (12). Nevertheless, because many patients would undergo several treatment cycles before achieving live birth (13), it is important to try and simplify treatment as much as possible for the benefit of the patient (8). Over the years, this process of simplification has occurred gradually and systematically. For example, oocyte collection is now performed by transvaginal US guidance under sedation and analgesia rather than laparoscopically under general anesthesia (10). Repeated flushing of the follicles at US-guided oocyte retrieval is no longer considered necessary, as aspiration alone produces a comparable oocyte recovery rate (11) and it has been shown that oocytes collected after repeated flushing have a poorer quality (14). This has allowed transvaginal US retrieval of developed oocytes to be performed in a much shorter time and with less discomfort to the patients. With the development of highly accurate vaginal US scanning for monitoring follicular growth, this has largely superseded the need for daily serum E2 measurements. The introduction of the long protocol of GnRH-a has simplified treatment even further. It has been found that, when this protocol is used, there is at least a 3-day window during which hcg can be administered with good results, and the rates of oocyte recovery, fertilization, and embryo cleavage remain optimal (5). This has led to the notion that the amount of monitoring of ovarian stimulation can be reduced greatly because there is no ideal day ofhcg administration that has to be targeted. In practice, this means that a patient only requires two or three US scans per cycle and no serum E2 measurements for monitoring the time of hcg administration (5). This simplicity of monitoring cannot be achieved necessarily if the short protocol of GnRH -a is used (15). Unfortunately, the long protocol of GnRH-a administration is associated with a significant practical problem, namely the variable length of time needed to achieve pituitary desensitization. Most patients achieve pituitary desensitization within 10 to 14 days of GnRH-a therapy (9) and some do so after as little as 7 days (16, 17). However, a proportion will not have achieved pituitary desensitization even after 2 weeks. Although women who require extended GnRH-a administration do equally well as those who achieve desensitization quickly, in terms of number of oocytes recovered, fertilization, and PRs (18), nevertheless, the prolongation of the treatment with repeated scans and venepunctures adds to the stress of treatment. To complicate matters, it remains uncertain whether it is necessary to achieve basal concentrations of serum E2 before commencing gonadotropin stimulation. The aim of the long protocol is to suppress pituitary responsiveness, and to prevent a premature surge of LH and perturbations of LH secretion. Measurement of serum E2 concentrations as a reflection of pituitary desensitization generally is used because it is too tedious to be performing routine GnRH or E2 benzoate challenge tests. It has been shown that there is a variable length of time needed to achieve pituitary suppression depending on the end point chosen. Haines et al. (19) compared the frequency with which pituitary suppression by GnRH-a was achieved according to hormonal (serum LH <5 mlu/ml [<5 lull], serum E2 < pg/ ml [< 100 pmol/ld and US (no follicles > 10 mm) criteria. They found that after 3 weeks of administration of intranasal buserelin acetate in a dose of 300 /-Lg three times daily, pituitary suppression was achieved in 85.6% of cases according to the LH level, 47.9% according to the E21evel, and 81.2% according to US criteria. All three criteria were met in only 11.5% of cases (19). Neither E2 nor LH levels were predictive of the sonographic evidence of pituitary suppression nor did they correlate with IVF outcome (19). Similarly, Bider et al. (17) administered 1.5 mg SC buserelin acetate followed by intranasal 1.2 mg buserelin acetate for 3 weeks. They found that suppression of pituitary activity was achieved after 6 days of bus ere lin acetate but serum E21evels continued to decline for the next 3 weeks to <20 pg/ml (conversion factor to SI unit, 3.67). Finally, Wren et al. (16) have shown that most patients on the long buserelin acetate regimen have serum E2 levels <27.24 pg/ml «100 pmol/l) within 7 days. The 794 Shaker et al. Progestogens and pituitary desensitization in IVF Fertility and Sterility
5 exceptions were patients with polycystic ovaries or those who developed ovarian cysts as a result of the GnRH-a administration. Most recently, Jenkins et al. (20) have shown that, in patients who develop as ovarian cyst after GnRH-a administration, the serum E2 level can remain elevated, even though pituitary desensitization has been achieved as shown by a negative GnRH challenge test. Various workers have used different serum E2 levels as indicative of pituitary suppression, ranging from <27.24 to pg/ml «100 to 200 pmolll) (18). A large number of patients in the present study had a rapid decline of serum E2 concentrations to <54.48 pg/ml «200 pmolll) after the menstrual bleed but the decline then slowed and it took many days for the levels to drop to <27.24 pg/ml «100 pmolll). If a serum E2 concentration of pg/ml (200 pmolll) was taken as the cutoff point, then only 13.63% of patients in group 1 would not have been suppressed, 12 days after recruitment, compared with 24.13% in group 2. The presence of ovarian cysts (> 10 mm in diameter) on the day of commencing hmg therapy was not detrimental to the outcome of treatment. This is consistent with our previous observation that aspiration of such cysts did not improve the outcome of treatment (21). In summary, there are varying criteria for assessing whether pituitary suppression has been achieved when the long regimen of buserelin acetate is used. It appears that of the different criteria, it generally takes longest for serum E2 concentrations to reach basal levels. Administration of an injection of progestogen hastens the onset of withdrawal bleeding and it well may be sufficient to commence gonadotropin stimulation once a menstrual bleed has occurred, without actually waiting for the serum E2 levels to be <27.24 pg/ml «100 pmolll). In the present study, the PRs were higher in the group that was given Gestone. A larger study will be needed to determine if the difference is indeed a significant one. REFERENCES 1. Tan S L, Maconochie N, Doyle P, Campbell S, Balen A, Bekir J, et al. Cumulative conception and live birth rates after in vitro fertilization with and without the use oflong, short, and ultrashort regimens of the gonadotropin releasing hormone agonist buserelin. Am J Obstet Gynecol 1994; 171: Neveu S, Hedon B, Bringer J, Chinchole J M, Arnal F, Hu me au C, et al. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril 1987;47: Tan SoL, Kingsland C, Campbell S, Mills C, Bradfield J, Alexander N, et al. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. Fertil Steril 1992;57: Balen A, Tan SoL, MacDougal MJ, Jacobs HS. Miscarriage rates following in vitro fertilization are increased in women with polycystic ovaries and reduced after desensitization with buserelin. Hum Reprod 1993;8: Tan SoL, Balen A, EI Hussein E, Mills C, Campbell S, Yovich J, et al. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization. Fertil Steril 1992;57: Dimitry ES, Bates SA, Oskarsson T, Magara R, Winston RML. Programming in vitro fertilization for a 5- or 3-day week. Fertil Steril 1991;55: Abdalla HI, Baber R, Leonard T, Kirkland A, Mitchell A, Power M, et al. Timed oocyte collection in an assisted conception programme using GnRH-analogue. Hum Reprod 1989; 4: Tan SoL. Simplifying in-vitro fertilization therapy. Curr Opin Obstet Gynecol 1994;6: Fleming R, Jamieson ME, Coutts JRT. The use of GnRHanalogs in assisted reproduction. In: Matson PL, Lieberman BA, editors. Clinical IVF forum. Current views in assisted reproduction. Manchester, United Kingdom: Manchester University Press, 1990: Tan SoL, Bennett S, Parsons J. Surgical techniques of oocyte collection and embryo transfer. Br Med Bull 1990;46: Tan SoL, Waterstone J, Wren M, Parsons J. A prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound directed oocyte recovery. Fertil Steril 1992;58: Tan SoL, Doyle P, Machonochie N, Edwards RG, Balen A, Bekir J, et al. Pregnancy and birth rates of live infants after in vitro fertilization in women with and without previous in vitro fertilization pregnancies: a study of eight thousand cycles at one center. Am J Obstet Gynecol 1994; 170: Tan SoL, Royston P, Campbell S, Jacobs HS, Betts J, Mason BA, et al. Cumulative conception and live birth rates after invitro fertilization. Lancet 1992;339: EI Hussein E, Balen A, Tan SL. A prospective study comparing the outcome of oocytes retrieved in the aspirate with those retrieved in the flush during transvaginal ultrasound directed oocyte recovery for in-vitro fertilization. Br J Obstet Gynaecol 1992;99: Clark L, Stanger J, Brinsmead M. Prolonged follicular stimulation decreases pregnancy rates after in vitro fertilization. Fertil Steril 1991;55: Wren M, Tan SL, Waterstone J, Parsons J. The optimum dose and mode of administration of luteinizing hormone releasing hormone analogue in in-vitro fertilization: a comparison of three regimens. Hum Reprod 1991;6: Bider D, Ben-Rafael Z, Shalev J, Goldenberg M, Mashiach S, Blankstein J. Pituitary and ovarian suppression rate after high dosage of gonadotropin-releasing hormone agonist. Fertil Steril 1989;51: Ibrahim ZHZ, Matson PL, Critchlow JD, Newman MC, Horne G, Hughes S, et al. Use of buserelin in an IVF programme for pituitary-ovarian suppression prior to ovarian stimulation with exogenous gonadotrophins. Hum Reprod 1990;5: Haines C, Loong E, Chan M, Chung T. A comparison ofhormonal and ultrasound assessment of pituitary suppression after pretreatment with a gonadotropin releasing hormone. agonist. lnt J Fertil 1993;38: Jenkins JM, Anthony FW, Lee A, Masson GM, Thomas E. Persistent elevation of serum estradiol levels by functional ovarian cysts despite effective pituitary desensitization with GnRH agonists. Clin Endocrinol (OxD 1994;40: Rizk B, Tan SL, Kingsland C, Steer C, Mason BA, Campbell S. Ovarian cyst aspiration and the outcome of in vitro fertilization. Fertil Steril 1990;54: Vol. 64, No.4, October 1995 Shaker et al. Progestogens and pituitary desensitization in IVF 795
Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol
Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko
More informationA prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound-directed oocyte recovery
FERTILITY AND STERILITY Vol. 58, No.2, August 1992 Copyright e 1992 The American Fertility Society Printed on acid-free paper in U.S.A. A prospective randomized study comparing aspiration only with aspiration
More informationOvarian response in three consecutive in vitro fertilization cycles
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in
More informationThe outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology
Human Reproduction vol.14 no.1 pp.167 171, 1999 The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology Lawrence Engmann 1,2,5, Noreen Maconochie
More informationEffects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment
FERTILITY AND STERILITY VOL. 74, NO. 5, NOVEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects of functional
More informationProgramming in vitro fertilization for a 5- or 3-day week
Ass~st.d.reproductive tec"no'ogy FERTILITY AND STERILITY Copyright I[J 1991 The American Fertility Society Printed on acid-free paper in U.S.A. Programming in vitro fertilization for a 5- or 3-day week
More informationA prospective randomized study comparing needles of different diameters for transvaginal ultrasound-directed follicle aspiration
FERTILITY AND STERILITY Copyright 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. A prospective randomized study comparing needles of different diameters for transvaginal
More informationTimur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D.
FERTILITY AND STEFULI~ Vol. 68, No. 3, September 1997 Copyright 1997 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Published by Elsevier Science Inc. Follicle-stimulating
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationIn Vitro Fertilization and Embryo Transfer
Acta Medica et Biologica Vol. 41, No.4, 171-176, 1993 The Influence of Low Ovarian Response on the Results of In Vitro Fertilization and Embryo Transfer Hirofumi HIRASAWA Department of Obstetrics and Gynecology,
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationNew York Science Journal 2014;7(4)
The Minimal Stimulation Protocol for ICSI: An Alternative Protocol for Ovarian Stimulation Adel Elsayed Ibrahim, MD Assisted Reproductive Unit Azhar University Adel.sayed29@gmail.com Abstract: Background:
More informationOvarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy
Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human
More informationA comparative study between agonist and antagonist protocol for ovarian stimulation in art cycles at a rural set up in South Gujarat
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Nadkarni PK et al. Int J Reprod Contracept Obstet Gynecol. 2015 Jun;4(3):617-621 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More information(BMI)=18.0~24.9 kg/m 2 ;
33 10 Vol.33 No.10 2013 10 Oct. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.10.0672 E-mail: randc_journal@163.com - ( 400013) : () GnRH-a - () : IVF- ET 233 A (I~II 102 ) B (III~IV
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationBulent Urman, M.D.* Margo R. Fluker, M.D. Basil Ho Yuen, M.B., Ch.B.t
FERTILITY AND STERILITY Copyright c 1992 The American Fertility Society Vol. 57, No.6, June 1992 Printed on acid-free paper in U.S.A. The outcome of in vitro fertilization and embryo transfer in women
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationin vitro fertilization
FERTILITY AND STERILITY VOL 69, NO. 6, JUNE 1998 Copyright (#1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Elevated levels of basal
More informationOriginal Article. Fauzia HaqNawaz 1*, Saadia Virk 2, Tasleem Qadir 3, Saadia Imam 3, Javed Rizvi 2
Original Article Comparison of Letrozole and Clomiphene Citrate Efficacy along with Gonadotrophins in Controlled Ovarian Hyperstimulation for Intrauterine Insemination Cycles Fauzia HaqNawaz 1*, Saadia
More informationGonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome
FERTILITY AND STERILITY Copyright e 1993 The American Fertility Society Vol. 59, No.3, March 1993 Printed on acid-free paper in U.S.A. Gonadotropin-releasing hormone agonist reduces the miscarriage rate
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationLaboratoires Genevirer Menotrophin IU 1.8.2
Important missing information VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Infertility is when a woman cannot get pregnant (conceive) despite having regular unprotected sexual
More informationOvarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact
Human Reproduction Page 1 of 5 Hum. Reprod. Advance Access published October 27, 2005 doi:10.1093/humrep/dei371 Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and
More informationIn vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome
Assisted reproductive techno.logy FERTILITY AND STERILITY Vol. 60, No.5, November 1993 Copyright 199a The American Fertility Society Printed on acid-free paper in U. S. A. In vitro fertilization and embryo
More informationFertility care for women diagnosed with cancer
Saint Mary s Hospital Department of Reproductive Medicine Information for Patients Fertility care for women diagnosed with cancer Contents Page Overview... 2 Our service... 2 Effects of cancer treatment
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationEffect of ovarian stimulation on oocyte quality and embryonic aneuploidy: a prospective, randomised controlled trial
FULL PROJECT TITLE: Effect of ovarian stimulation on oocyte quality and embryonic aneuploidy: a prospective, randomised controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM)
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationAssisted reproductive technology
Assisted reproductive technology FERTILITY AND STERILITY Vol. 60, No.2, August 1993 Copyright 'c; 199:~ The American Fertility Society Printed on acid-free paper in U. S. A. Natural cycle in vitro fertilization-embryo
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationArticle Prediction of pituitary down-regulation by evaluation of endometrial thickness in an IVF programme
RBMOnline - Vol 8. No 5. 2004 595-599 Reproductive BioMedicine Online; www.rbmonline.com/article/1065 on web 17 March 2004 Article Prediction of pituitary down-regulation by evaluation of endometrial thickness
More informationA controlled study of gonadotropin-releasing hormone agonist (buserelin acetate*) for folliculogenesis in routine in vitro fertilization patients
FERTILITY AND STERILITY Copyright" 1991 The American Fertility Society Vol. 56, No. 3, September 1991 Printed on acid-free paper in U.S.A. A controlled study of gonadotropin-releasing hormone agonist (buserelin
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationCONTROLLED OVARIAN HYPERSTIMULATION AND OOCYTE RETRIEVAL : CLINICAL INPUTS. DR Priyanka Sinha MD OB-GYN MUMBAI, INDIA
CONTROLLED OVARIAN HYPERSTIMULATION AND OOCYTE RETRIEVAL : CLINICAL INPUTS DR Priyanka Sinha MD OB-GYN MUMBAI, INDIA LEARNING OBJECTIVE Introduction Ovarian stimulation protocols Comparison of different
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationProspective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program
FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U. s. A. Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in
More informationThree-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age
FERTILITY AND STERILITY VOL. 79, NO. 1, JANUARY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Three-dimensional
More informationWOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IVF WITH EMBRYO TRANSFER
*40639* 40639 WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IVF WITH EMBRYO TRANSFER I have requested treatment by the physicians and (Print Patient s name) staff of the Women & Infants Fertility
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationIranian Journal of Reproductive Medicine Vol. 2. No.1 pp 29-33, 2004
Efficacy of Low Dose, Long-acting Gonadotropin Releasing Hormone Analogues (GnRH-a) Compared with Daily Injections of Short-acting GnRH-a in ART Cycles Robabeh Taheripanah M.D. 1, Mohammad A. Karimzadeh
More informationWhich is the Best Protocol of Ovarian Stimulation Prior to Artificial Insemination by Donor
Journal of Reproduction & Contraception doi: 10.7669j.issn.1001-7844.2014.01.0041 2014 Mar.; 25(1):41-48 E-mail: randc_journal@163.com Which is the Best Protocol of Ovarian Stimulation Prior to Artificial
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationProspective study of short and ultrashort regimens of gonadotropinreleasing hormone agonist in an in vitro fertilization program
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Prospective study of short and ultrashort regimens of gonadotropinreleasing hormone agonist in
More informationEndometrial blood flow response to hormone replacement therapy in women with premature ovarian failure: a transvaginal Doppler study
. M.,nopause FERTILITY AND STERILITY Vol. 63, No.3, March 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. s. A. Endometrial blood flow response to hormone
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationPrognostic value of day 3 estradiol on in vitro fertilization outcome*
FERTILITY AND STERILITY Vol. 64, No.6, December 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prognostic value of day 3 estradiol on in vitro fertilization
More informationDepartment of Gynaecology and Reproductive Medicine, University Hospital, University of Western Ontario, London, Ontario, Canada
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationDepartment of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. The effect of baseline complex ovarian cysts on in vitro fertilization outcome*t Elizabeth A.
More informationEndometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY
Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Natural Cycle FET Protocol for endometrial preparation N FET, including modified N FET HRT FET:
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More information' ' ' ' ' ' ' ' COMPARISON BETWEEN HIGHLY PURIFIED--FSH AND HMG FOR SUPEROVULATION IN WOMEN UNDERGOING IN VITRO FERTILIZATION ORIGINAL RESEARCH
' ' ' ' ORIGINAL RESEARCH ' ' ' ' COMPARISON BETWEEN HIGHLY PURIFIED--FSH AND HMG FOR SUPEROVULATION IN WOMEN UNDERGOING IN VITRO FERTILIZATION Pierre Miron, MD, FRCSC, 1 Robert Casper, MD, FRCSC,2 Louise
More informationAmir Ravhon, M.D., Ramon Aurell, M.D., Henrietta Lawrie, M.B., B.S., Raul Margara, M.D., and Robert M. L. Winston, F.R.C.O.G.
FERTILITY AND STERILITY VOL. 73, NO. 2, FEBRUARY 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. The significance
More informationPerformance of patients with a ''frozen pelvis" in an in vitro fertilization program
FERTILITY AND STERILITY Copyright 1987 The American Fertility Society Printed in U.8A. Performance of patients with a ''frozen pelvis" in an in vitro fertilization program David Molloy, F.R.A.C.O.G.*t
More informationEffect of baseline ovarian cysts on in vitro fertilization and gamete intrafallopian transfer cycles*
FERTILITY AND STERILITY Copyright 1991 The American Fertility Society Printed on acid-free paper in U.S.A. Effect of baseline ovarian cysts on in vitro fertilization and gamete intrafallopian transfer
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationINDICATIONS OF IVF/ICSI
PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian
More informationWOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1.
*40675* 40675 MR-838 (9-2017) WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1. I, and (Print Patient s name) (Print
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationUniversal Embryo Cryopreservation: Frozen versus Fresh Transfer. Zaher Merhi, M.D.
Universal Embryo Cryopreservation: Frozen versus Fresh Transfer Zaher Merhi, M.D. Disclosure: None Fewer complications with IVF 1.5% children in US are born through ART 1.1 million children since 2006
More informationComparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,
More informationThe effects of prior gravidity on the outcomes of ovum donor and own oocyte cycles
FERTILITY AND STERILITY Vol. 65, No.3, March 1996 Copyright t';, 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. s. A. The effects of prior gravidity on the outcomes of
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...
More informationInformation Booklet. Exploring the causes of infertility and treatment options.
Information Booklet Exploring the causes of infertility and treatment options www.ptafertility.co.za info@ptafertility.co.za +27 12 998 8854 Faith is taking the first step even if you don t see the whole
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationPatient Information: Patient Name: Date of Birth:
Weill Cornell Medicine Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine Informed Consent for Oocyte (Egg) Cryopreservation Patient Information: Part 1: I have requested to be treated
More informationPatient Overview: Invitro Fertilisation
Patient Overview: Overview IVF stands for in-vitro fertilisation i.e. literally fertilisation in a glass dish. You may also hear the term ART used which stands for Assisted Reproductive Technologies. IVF
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationUtility of in vitro fertilization at diagnostic laparoscopy*
FERTILITY AND STERILITY Copyright" 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Utility of in vitro fertilization at diagnostic laparoscopy* Paul R. Gindoff, M.D.t Jerry L.
More informationFertility assessment and assisted conception
Fertility assessment and assisted conception Dr Geetha Venkat MD FRCOG Director Pulse Learning Women s health 14 September 2016 Disclosure statement Dr Venkat is a director of Harley Street Fertility Clinic.
More informationManish Banker. Declared receipt of grants; member of a company advisory board, board of director or similar group
Manish Banker Nova IVI Fertility Pulse Women's Hospital Gujarat, India Declared receipt of grants; member of a company advisory board, board of director or similar group The Indian point of view Manish
More informationCumulative probability of live birth after three in vitro fertilization/intracytoplasmic sperm injection cycles
FERTILITY AND STERILITY VOL. 77, NO. 3, MARCH 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Cumulative probability
More informationAims of this talk. Evaluation & investigation. Basic treatments/options including ovulation induction & Intra uterine Insemination
Basic treatments/options including ovulation induction & Intra uterine Insemination Karen Woodcock Clinical Nurse Specialist/ Nurse Manager Fertility & Assisted Conception Unit Countess of Chester NHS
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24875
More informationA mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort
Chapter 6 A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Heijnen E.M., Eijkemans M.J., De Klerk C., Polinder S., Beckers N.G., Klinkert E.R.,
More informationBlastocyst-stage embryo transfer in patients who failed to conceive in three or more day 2 3 embryo transfer cycles: a prospective, randomized study
FERTILITY AND STERILITY VOL. 81, NO. 3, MARCH 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Blastocyst-stage embryo transfer
More informationIVF Patient Information
What is IVF? IVF (In Vitro Fertilisation) is a treatment by which fertilisation of eggs by sperm takes place outside the body in a dish in an IVF laboratory. An ovary has a pool of immature eggs. In a
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationEstradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success
DOI 10.1007/s13224-014-0515-6 ORIGINAL ARTICLE Estradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success Prasad Sudha Kumar Yogesh Singhal Megha Sharma Shashi Received: 27
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationLiyan Duan 1, Shihua Bao 1, Kunming Li 1, Xiaoming Teng 1, Ling Hong 1 and Xiaoyu Zhao 2. Abstract. Introduction
doi:10.1111/jog.13305 J. Obstet. Gynaecol. Res. Vol. 43, No. 6: 1037 1042, June 2017 Comparing the long-acting and short-acting forms of gonadotropin-releasing hormone agonists in the long protocol of
More informationPoor & Hyper responders: what is the best approach?
Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationPuerto Rico Fertility Center
Puerto Rico Fertility Center General Information of the In-Vitro Fertilization Program Dr. Pedro J. Beauchamp First test-tube baby IN PUERTO RICO Dr. Pedro Beauchamp with Adlin Román in his arms. Paseo
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationInfertility: A Generalist s Perspective
Infertility: A Generalist s Perspective Learning Objectives Fertility and Lifestyle: Patient education Describe the basic infertility workup Basic treatment strategies unexplained Heather Huddleston, MD
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationEgg donation in an in vitro fertilization program: an alternative approach to cycle synchronization and timing of embryo transfer
FERTILITY AND STERILITY Copyright tl 1989 The American Fertility Society Printed on acid-free paper in U. S.A. Egg donation in an in vitro fertilization program: an alternative approach to cycle synchronization
More information